Any current/future new fundraising through debt or equity?

As of now, Black Rose Industries Limited does not see any major requirement for fundraising through debt or equity. The company currently has substantial results in its accounts to fund planned projects such as R&D facility, collaboration with the Japanese company, and land acquisition. Any decision on further fundraising will be made later as these projects progress. The management indicated they do not anticipate needing fund raising at this stage.

Any current/future capex/capital investment/strategic investment?

Planned capex around ₹35-40 crore for current projects including new R&D facility, Japanese collaboration, and land acquisition. Specialty chemicals plant capex estimated at ₹20-30 crore, pending environmental clearance. Land acquisition of about 20 acres for future expansions already shortlisted. Current projects can largely be implemented within existing plant premises (Jhagadia), with additional land for future products. Low capex requirement due to advanced technology and scale, leading to healthy ROIC though exact figures not specified. Toll manufacturing projects with US and Eu

Future growth expectations in sales/revenue/volumes?

Growth in revenue and volumes anticipated mainly from existing products this year; new product revenue expected from next year (FY26 onward). Chemical Distribution business poised for better performance with strong supplier support and stable international logistics aiding higher sales and good margins. Existing manufacturing volumes expected to increase supported by healthy margins and supplier relationships. Capacity expansions planned but dependent on statutory approvals; capacity increases can be implemented relatively quickly once approvals are in place. Polyacrylamide Solid produ

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue growth is expected mainly from existing manufacturing products this year, with new products and ventures contributing from next year (FY26 onwards). Polyacrylamide solid product manufacturing revenue expected to start in FY26, with potential full capacity revenue around ₹250 crore. Margins have more than doubled recently; there is headroom for margin expansion, especially as Chinese market conditions improve and logistics issues ease. Growth in volumes and margins expected as suppliers support volume increases and demand picks up globally and domestically. Efforts to add new pr

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected orderbook or pending orders in specific numeric terms. Mr. Ambarish Daga highlighted that the company adds new customers every quarter through a lengthy product validation and trial process, indicating a growing order pipeline, especially with large multinational customers. Initial allocations from large MNCs are small but expected to increase gradually, leading to significant growth in the acrylamide business. The company emphasizes strong partnerships and loyalty over customer size for order growth. Due to the nature of appro

IN US

Sale is live|00:00:00left today

Black Rose Industries LtdQ1 FY24Chemicals & Petrochemicals

Black Rose Industries Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹90.2P/E: 21.8Market Cap: ₹491 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Growth in revenue and volumes anticipated mainly from existing products this year; new product revenue expected from next year (FY26 onward).
→Chemical Distribution business poised for better performance with strong supplier support and stable international logistics aiding higher sales and good margins.
→Existing manufacturing volumes expected to increase supported by healthy margins and supplier relationships.
→Capacity expansions planned but dependent on statutory approvals; capacity increases can be implemented relatively quickly once approvals are in place.
→Polyacrylamide Solid product expected to start revenue generation in FY26 with initial capacity of 10,000 MT, estimating ~₹250 crore at full utilization.
→Larger customers (mostly multinational companies) dominate sales; allocations from big customers increasing gradually, indicating potential for high order volumes.
→Margins seen to have room for expansion as Chinese market stabilizes and logistics improvements continue.
→Uncertainty remains due to market variables, but company optimistic about stable or improving demand and pricing conditions.

Margin guidance

Category 3

→Revenue growth is expected mainly from existing manufacturing products this year, with new products and ventures contributing from next year (FY26 onwards).
→Polyacrylamide solid product manufacturing revenue expected to start in FY26, with potential full capacity revenue around ₹250 crore.
→Margins have more than doubled recently; there is headroom for margin expansion, especially as Chinese market conditions improve and logistics issues ease.
→Growth in volumes and margins expected as suppliers support volume increases and demand picks up globally and domestically.
→Efforts to add new products and expand distribution reach in new geographies will support top-line growth.
→Capital expenditure is moderate (~₹35-40 crore), supporting sustainable high ROIC due to low CapEx intensity.
→Approval and trial timelines make exact timing uncertain; the company remains cautiously optimistic but avoids definitive forecasts.
→Overall EPS growth is anticipated due to volume increase, margin improvement, and operational leverage.

3 more insights locked — sign up free to unlock

Fundraise plans

→As of now, Black Rose Industries Limited does not see any major requirement for fundraising through debt or equity.
→The company currently has substantial results in its accounts to fund planned projects such as R&D facility, collaboration with the Japanese company, and land acquisition.
→Any decision on further fundraising will be made later as these projects progress.
→The management indicated they do not anticipate needing fund raising at this stage.

Order book

→The transcript does not explicitly mention the current or expected orderbook or pending orders in specific numeric terms.
→Mr. Ambarish Daga highlighted that the company adds new customers every quarter through a lengthy product validation and trial process, indicating a growing order pipeline, especially with large multinational customers.
→Initial allocations from large MNCs are small but expected to increase gradually, leading to significant growth in the acrylamide business.
→The company emphasizes strong partnerships and loyalty over customer size for order growth.
→Due to the nature of approvals and trials, orderbook build-up is gradual but expected to strengthen over upcoming quarters.
→No quantitative data on orderbook size or pending orders was provided during the webinar.

Capex plans

Yes

→Planned capex around ₹35-40 crore for current projects including new R&D facility, Japanese collaboration, and land acquisition.
→Specialty chemicals plant capex estimated at ₹20-30 crore, pending environmental clearance.
→Land acquisition of about 20 acres for future expansions already shortlisted.
→Current projects can largely be implemented within existing plant premises (Jhagadia), with additional land for future products.
→Low capex requirement due to advanced technology and scale, leading to healthy ROIC though exact figures not specified.
→Toll manufacturing projects with US and European customers ongoing, but no major capex updates due to confidentiality.
→Expansion capacity increases (50-100%) feasible with minimal capex; statutory clearances take 6-12 months.
→New product commercialization (e.g., Polyacrylamide Solid) expected revenue ₹250 crore at full capacity; ramp-up expected FY26-FY27.

How does Black Rose Industries Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Black Rose Industries Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Black Rose Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio